Abstract
DM 232 and DM 235 are novel antiamnesic compounds structurally related to ampakines. The involvement of AMPA receptors in the mechanism of action of DM 232 and DM 235 was, therefore, investigated in vivo and in vitro. Both compounds (0.1 mg/kg−1 i.p.) were able to reverse the amnesia induced by the AMPA receptor antagonist NBQX (30 mg/kg−1 i.p.) in the mouse passive avoidance test. At the effective doses, the investigated compounds did not impair motor coordination, as revealed by the rota rod test, nor modify spontaneous motility and inspection activity, as revealed by the hole board test. DM 232 and DM 235 reversed the antagonism induced by kynurenic acid of the NMDA-mediated release of [3H]NA in the kynurenate test performed in rat hippocampal slices. This effect was abolished by NBQX. DM 232 increases, in a concentration dependent manner, excitatory synaptic transmission in the rat hippocampus in vitro. These results suggest that DM 232 and DM 235 act as cognition enhancers through the activation of the AMPA-mediated neurotransmission system.
Similar content being viewed by others
References
Arai A, Lynch G (1992) Factors regulating the magnitude of long-term potentiation induced by theta pattern stimulation. Brain Res 598:173–184
Arai A, Kessler M, Xiao P, Ambros-Ingerson J, Rogers G, Lynch G (1994) A centrally active drug that modulates AMPA receptor gated currents. Brain Res 638:343–346
Arai AC, Kesler M, Rogers G, Lynch G (2000) Effects of the potent ampakine CX614 on hippocampal and recombinant AMPA receptors: interactions with cyclothiazide and GYKI 52466. Mol Pharmacol 58:802–813
Bara H, Hainfellner JA, Kepplinger B, Maral PR, Schmidt H, Budka H (2000) Kynurenic acid metabolism in the brain of HIV-1 infected patients. J Neural Transm 107:1127–1138
Baran H, Jellinger K, Deecke L (1999) Kynurenine metabolism in Alzheimer’s disease. J Neural Transm 106:165–181
Bleakman, Lodge D (1998) Neuropharmacology of AMPA and kainate receptors. Neuropharmacology 37:1187–1204
Bliss TVP, Collingridge GL (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361:31–39
Burchuladze R, Rose SP (1992) Memory formation in day-old chicks requires NMDA but not non-NMDA glutamate receptors. Eur J Neurosci 4:533–538
Cammarota M, Izquierdo I, Wolfman C, Levi de Stein M, Bernabeu R, Jerusalinsky D, Medina JH (1995) Inhibitory avoidance training induces rapid and selective changes in [3H]AMPA receptor binding in the rat hippocampal formation. Neurobiol Learn Mem 64:257–264
Cammarota M, Bernabeu R, Izquierdo I, Medina JH (1996) Reversible changes in hippocampal 3H-AMPA binding following inhibitory avoidance training in the rat. Neurobiol Learn Mem 66:85–88
Filliat P, Pernot-Marino I, Baubichon D, Lallement G (1998) Behavioural effect of NBQX, a competitive antagonisty of the AMPA receptors. Pharmacol Biochem Behav 59:1087–1092
Ghelardini C, Galeotti N, Gualtieri F, Manetti D, Bucherelli C, Baldi E, Bartolini A (2002a) The novel nootropic compound DM 232 (unifiram) ameliorates memory impairment in mice and rats. Drug Dev Res 56:23–32
Ghelardini C, Galeotti N, Gualtieri F, Romanelli MN, Bucherelli C, Baldi E, Bartolini A (2002b) DM 235 (sunifiram): a novel nootropic with potential as cognitive enhancer. Naunyn-Schmiedebergs Arch Pharmacol 365:419–426
Gouliaev AH, Senning A (1994) Piracetam and other structurally related nootropics. Brain Res Rev 19:180–222
Gramsbergen JB, Schimdt W, Turski WA, Schwarz R (1992) Age related changes in kynurenic acid production in rat brain. Brain Res 588:1–5
Granger R, Deadwyler S, Davis M, Moskovitz B, Kessler M, Rogers G, Lynch G (1996) Facilitation of glutamate receptors reverses an age-associated memory impairment in rats. Synapse 22:332–337
Gualtieri F, Manetti D, Romanelli MN, Ghelardini C (2002) Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs. Curr Pharm Design 8:125–138
Hampson RE, Rogers G, Lynch G, Deadwyler SA (1998a) Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance. J Neurosci 18:2740–2747
Hampson RE, Rogers G, Lynch G, Deadwyler SA (1998b) Facilitative effects of the ampakine CX516 on short-term memory in rats: correlations with hippocampal neuronal activity. J Neurosci 18:2748–2763
Hodgkiss JP, Kelly JS (2001) Effect of FK960, a putative cognitive enhancer, on synaptic transmission in CA1 neurons of rat hippocampus. J Pharmacol Exp Ther 297:620–628
Hollmann M, Heinemann S (1994) Cloned glutamate receptors. Annu Rev Neurosci 17:31–108
Jarvik ME, Kopp R (1967) An improved one-trial passive avoidance learning situation. Psychol Rep 21:221–224
Kim M, Campeau S, Falls WA, Davis M (1993) Infusion of the non-NMDA receptor antagonist CNQX into the amygdala blocks the expression of fear-potentiated startle. Behav Neural Biol 59:5–8
Kuribara H, Higuchi Y, Takadoro S (1977) Effects of central depressants on rota-rod and traction performances in mice. Jpn J Pharmacol 27:117–126
Larson J, Lieu T, Petchpradub V, LeDuc B, Ngo H, Rogers GA, Lynch G (1995) Facilitation of olfactory learning by a modulator of AMPA receptors. J Neurosci 15:8023–8030
Lynch G, Kessler M, Rogers G, Ambros-Ingerson J, Granger R, Schehr RS (1996) Psychological effects of a drug that facilitates brain AMPA receptors. Int Clin Psychopharmacol 11:13–19
Malenka RC, Nicoll RA (1993) NMDA-receptor-dependent synaptic plasticity: multiple forms and mechanisms. Trends Neurosci 16:521–527
Manetti D, Borea PA, Ghelardini C, Gualtieri F, Romanelli MN, Scapecchi S, Valle G (1997) Reduced-flexibility hybrids of the nicotinic agonists 1,1-dimethyl-4-acetylpiperazinium iodide and 2-(dimethylamino)methyl-5-methyl-cyclopentanone methiodide. Med Chem Res 7:301–312
Manetti D, Ghelardini C, Bartolini A, Bellucci C, Dei S, Galeotti N, Gualtieri F, Romanelli MN, Scapecchi S, Teodori E (2000a) Design, synthesis and preliminary pharmacological evaluation of 1,4-diazabicyclo[4.3.0.]nonan-9-ones as a new class of highly potent nootropic agents. J Med Chem 43:1969–1974
Manetti D, Ghelardini C, Bartolini A, Dei S, Galeotti N, Gualtieri F, Romanelli MN, Teodori E (2000b) Molecular simplification of 1,4-diazabicyclo[4.3.0.]nonan-9-ones gives piperazine derivatives that maintain high nootropic activity. J Med Chem 43:4499–4507
Moroni F (1999) Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur J Pharmacol 375:87–100
Moroni F, Russi P, Lombardi G, Beni M, Carla V (1988) Presence of kynurenic acid in the mammalian brain. J Neurochem 51:177–180
Novak L, Bregestovski P, Asher P, Herbert A, Prochantz A (1984) Magnesium gates glutamate-activated channels in mouse central neurones. Nature (Lond) 307:462–465
Pittaluga A, Pattarini R, Raiteri M (1995) Putative cognition enhancers reverse kynurenic acid antagonism at hippocampal NMDA receptors. Eur J Pharmacol 272:203–209
Pittaluga A, Vaccari D, Raiteri M (1997) The “kynurenate test”, a biochemical assay for putative cognition enhancers. J Pharmacol Exp Ther 283:82–90
Pittaluga A, Bonfanti A, Arvigo D, Raiteri M (1999) Aniracetam, 1-BCP and cyclothiazide differentially modulate the function of NMDA and AMPA receptors mediating enhancement of noradrenaline release in rat hippocampal slices. Naunyn-Schmiedebergs Arch Pharmacol 359:272–279
Pittaluga A, Feligioni M, Ghersi C, Gemignani A, Raiteri M (2001) Potentiation of NMDA receptor function through somatostatin release: a possible mechanism for the cognition-enhancing activity of GABA(B) receptor antagonists. Neuropharmacology 41:301–310
Pugliese AM, Passani MB, Pepeu G, Corradetti R (1996) Felbamate decreases synaptic transmission in the CA1 region of rat hippocampal slices. J Pharmacol Exp Ther 279:1100–1108
Quillfeldt JA, Schmitz PK, Walz R, Bianchin M, Zanatta MS, Medina JH, Izquierdo I (1994) CNQX infused into entorhinal cortex blocks memory expression, and AMPA reverses the effect. Pharmacol Biochem Behav 48:437–440
Sheardown MJ, Nielsen E O, Hansen AJ, Jacobsen P, Honorè T (1990) 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science 247:571–574
Staubli U, Perez Y, Xu FB, Rogers G, Ingvar M, Stone-Elander S, Lynch G (1994a) Centrally active modulators of glutamate receptors facilitate the induction of long-term potentiation in vivo. Proc Natl Acad Sci USA 91:11158–11162
Staubli U, Rogers G, Lynch G (1994b) Facilitation of glutamate receptors enhances memory. Proc Natl Acad Sci USA 91:777–781
Steele RJ, Stewart MG (1995) Involvement of AMPA receptors in maintenance of memory for a passive avoidance task in day-old domestic chicks (Gallus domesticus) Eur J Neurosci 7:1297–1304
Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45:309–379
Tocco G, Maren S, Shors TJ, Baudry M, Thompson RF (1992) Long-term potentiation is associated with increased [3H]AMPA binding in rat hippocampus. Brain Res 573:228–234
Turski WA, Nakamura M, Todd WP, Carpenter BK, Whetsell WO Jr, Schwarcz R (1988) Identification and quantification of kynurenic acid in human brain tissue. Brain Res 454:164–169
Yamada KA (2000) Therapeutic potential of positive AMPA receptor modulators in the treatment of neurological disease. Exp Opin Invest Drugs 9:765–768
Zivkovic I, Thompson DM, Bertolino M, Uzunov D, DiBella M, Costa E, Guidotti A (1995) 7-Chloro-3-methyl-3–4-dihydro-2H-1,2,4 benzothiadiazine S,S-dioxide (IDRA 21): a benzothiadiazine derivative that enhances cognition by attenuating DL-alpha-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA) receptor desensitization. J Pharmacol Exp Ther 272:300–309
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Galeotti, N., Ghelardini, C., Pittaluga, A. et al. AMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram). Naunyn-Schmiedeberg's Arch Pharmacol 368, 538–545 (2003). https://doi.org/10.1007/s00210-003-0812-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-003-0812-6